GH vs ICLR vs IQV Stock Comparison

Guardant Health, Icon and Iqvia Holdings Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.57B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
3 wins
ICLR Icon Plc
$194.65 +15.2% 1M +19.1% 1Y
Market cap
$14.99B
P/E
33.4x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
3 wins
IQV Iqvia Holdings Inc.
$264.96 +1.1% 1M +18.5% 1Y
Market cap
$43.71B
P/E
31.4x
Revenue (TTM)
$17.31B
Div. yield
–
Contract Research Healthcare
5 wins

Head to Head

11 decided of 12

Iqvia Holdings leads on 5 of the 12 questions below (Iqvia Holdings 5, Icon 3, Guardant Health 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGHICLRIQVLeader
Larger companyMarket capitalisation $19.57B $14.99B $43.71B IQV
Cheaper on earningsLower P/E, profitable companies only -40.4x 33.4x 31.4x IQV
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 19.0x 21.8x ICLR
Faster revenue growthRevenue growth, trailing twelve months +41.7% +1.8% +8.8% GH
More profitableNet margin, trailing twelve months -37.9% 5.4% 8.1% IQV
Better return on capitalReturn on invested capital — 4.7% 8.2% IQV
Less leveragedLower net debt / EBITDA — 2.3x 3.9x ICLR
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +61.2% +19.1% +18.5% GH
Better 5-year returnAnnualised price return, 5 years +7.9%/yr -7.4%/yr +0.8%/yr GH
Less volatileAnnualised volatility, 1 year 53.0% 74.9% 40.8% IQV
Higher overall scoreMean of the five percentile scores vs peers 27/100 78/100 71/100 ICLR

Percentile Scorecard

GHICLRIQV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGHICLRIQV
Valuation 15 #84 of 99 100 #1 of 11 80 #3 of 11
Growth 44 #50 of 89 50 #6 of 11 60 #5 of 11
Profitability 9 #84 of 92 80 #3 of 11 90 #2 of 11
Financial Health 54 #48 of 103 75 #4 of 13 25 #10 of 13
Shareholder Returns 13 #55 of 63 86 #2 of 8 100 #1 of 8
Overall 27 78 71
  • GH ranked among 103 companies in Healthcare Providers
  • ICLR ranked among 13 companies in Pharma Services
  • IQV ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGHICLRIQVSPY
1 month -6.9%+15.2%+1.1% -2.0%
3 months -3.5%+19.3%+11.9% -2.8%
6 months +59.8%+67.3%+56.7% +2.0%
Year to date +48.5%+6.8%+17.5% +10.6%
1 year +61.2%+19.1%+18.5% +12.2%
3 years +519.4%-27.1%+32.2% +68.1%
3 years, per year +83.7%-10.0%+9.7% +18.9%
5 years +46.1%-31.8%+4.0% +61.4%
5 years, per year +7.9%-7.4%+0.8% +10.1%
10 years —+142.7%+243.5% +248.5%
10 years, per year —+9.3%+13.1% +13.3%

Risk

MeasureGHICLRIQVSPY
Volatility, 1Y 53.0%74.9%40.8% 13.6%
Downside volatility, 1Y 50.7%87.1%39.9% 13.9%
Beta vs S&P 500, 1Y 1.321.290.71 1.00
Return / volatility, 1Y 1.150.250.45 0.90
Max drawdown, 5Y -85.0%-76.9%-51.5% -25.4%
From 52-week high -19.0%-9.7%-5.2% -3.2%
52-week high $187.22$215.48$279.38 $779.14
52-week low $78.60$80.08$156.66 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGHICLRIQV
P/E now vs peer median -42.0xmedian 22.4x 34.0xmedian 34.7x 31.3xmedian 34.7x
P/S now vs peer median 16.0xmedian 1.3x 1.8xmedian 2.5x 2.5xmedian 2.5x
EV/EBITDA now vs peer median -40.6xmedian 14.2x 16.0xmedian 29.1x 16.6xmedian 29.1x
P/FCF now vs peer median -88.0xmedian 19.0x 17.4xmedian 21.0x 21.0xmedian 21.0x
P/B now vs peer median -74.1xmedian 2.6x 1.6xmedian 1.6x 6.4xmedian 1.6x
PEG now vs peer median -72.47median 0.84 -11.35median 1.98 2.71median 1.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGHICLRIQV
Revenue $1.28B $8.23B $17.31B
Gross profit $833.70M $1.93B $5.72B
Operating income -$504.04M $718.25M $2.22B
Net income -$485.07M $448.66M $1.40B
Free cash flow -$232.15M $857.06M $2.08B
R&D $386.67M – –
EPS (diluted) $-3.61 $5.68 $8.35
Cash & equivalents $1.03B $808.98M $2.25B
Total debt – $3.38B $16.07B
Shares (diluted) 134.42M 78.97M 167.00M
Enterprise value $15.19B $11.76B $34.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGHICLRIQV
P/E -42.0x 34.0x 31.3x
P/FCF -88.0x 17.4x 21.0x
P/Operating cash flow -117.8x 14.5x 16.0x
P/S 16.0x 1.8x 2.5x
P/B -74.1x 1.6x 6.4x
P/Tangible book -67.9x 2.5x 21.3x
EV/EBITDA -40.6x 16.0x 16.6x
EV/EBIT -38.5x 24.3x 25.8x
EV/Revenue 15.2x 2.1x 3.3x
EV/FCF -83.6x 20.4x 27.6x
EV/Operating cash flow -111.9x 17.0x 20.9x
PEG (3Y EPS CAGR) -72.47 -11.35 2.71

Growth

14 metrics
MetricGHICLRIQV
Revenue growth (1Y) 41.7% 1.8% 8.8%
Revenue CAGR (3Y) 33.6% 0.9% 5.2%
Gross profit growth (1Y) 44.9% -13.4% 6.6%
Gross profit CAGR (3Y) – -6.5% 3.4%
Operating income growth (1Y) -13.9% 53.9% 1.7%
Operating income CAGR (3Y) 0.6% -7.0% 6.2%
Net income growth (1Y) -21.6% 55.9% 9.0%
Net income CAGR (3Y) -3.9% -4.4% 7.8%
EPS growth (1Y) -12.9% 30.1% 11.7%
EPS CAGR (3Y) 0.6% -3.0% 11.5%
Operating cash flow growth (1Y) 22.2% -9.9% -2.4%
Operating cash flow CAGR (3Y) 19.9% 15.8% 11.7%
Free cash flow growth (1Y) 11.5% -11.1% -6.0%
Free cash flow CAGR (3Y) 13.9% 18.4% 16.3%

Profitability

14 metrics
MetricGHICLRIQV
Gross margin 65.2% 23.4% 33.1%
EBITDA margin -37.4% 13.3% 20.0%
Operating margin -39.4% 8.7% 12.8%
Pretax margin -38.0% 6.3% 9.0%
Net margin -37.9% 5.4% 8.1%
FCF margin -18.2% 10.4% 12.0%
Operating cash flow margin -13.6% 12.5% 15.8%
Return on equity – 7.6% 21.4%
Return on assets -25.5% 4.3% 4.6%
Return on invested capital – 4.7% 8.2%
Return on capital employed -33.0% 5.3% 9.9%
Asset turnover 0.7x 0.5x 0.6x
Cash conversion (OCF / net income) 0.4x 2.3x 2.0x
Stock comp / revenue 16.5% 1.1% 1.8%

Financial Health

11 metrics
MetricGHICLRIQV
Debt / assets – 20.8% 52.7%
Debt / equity – 0.4x 2.4x
Net debt / EBITDA – 2.3x 3.9x
Debt / FCF – 3.9x 7.7x
Liabilities / assets 114.6% 43.8% 77.7%
Equity / assets -14.6% 56.2% 22.3%
Interest coverage -96.6x 3.4x 2.8x
Current ratio 3.6x 1.3x 0.8x
Quick ratio 3.3x 0.9x 1.0x
Cash ratio 2.8x 0.3x 0.3x
Altman Z-score 3.60 2.15 2.24

Shareholder Returns

7 metrics
MetricGHICLRIQV
Dividend yield – – –
Net buyback yield -2.0% 2.6% 2.8%
Shareholder yield -2.0% 2.6% 2.8%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGHICLRIQV
Forward P/E – 19.0xFY2026 21.8xFY2026
EPS, next fiscal year $-3.46FY2026 $10.26FY2026 $12.16FY2026
EPS growth, next FY – -18.1%FY2026 +2.0%FY2026
EPS growth, the year after – +20.1% +11.4%
Revenue, next fiscal year $1.43BFY2026 $8.54BFY2026 $18.65BFY2026
Revenue growth, next FY +45.5%FY2026 +3.5%FY2026 +14.4%FY2026
Revenue growth, the year after +26.0% -2.2% -3.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGHICLRIQV
Held by institutions 100.0% 100.0% 94.1%
Institutions holding 597 424 1,085
Change in shares held, QoQ -2.5% +5.5% +0.3%
Institutions buying 356 233 532
Institutions selling 180 139 424
Buyers to sellers 1.98 1.68 1.25

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GHICLRIQV
GH 1.00 0.25 0.31
ICLR 0.25 1.00 0.55
IQV 0.31 0.55 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GH, ICLR and IQV?

Iqvia Holdings (IQV) is the largest by market capitalisation: Guardant Health (GH) $19.57B, Icon (ICLR) $14.99B, Iqvia Holdings (IQV) $43.71B.

Which stock is cheaper, GH, ICLR and IQV?

Iqvia Holdings (IQV) trades on the lowest price-to-earnings ratio (Guardant Health (GH) -40.4x, Icon (ICLR) 33.4x, Iqvia Holdings (IQV) 31.4x). On next year's consensus earnings, Icon (ICLR) is cheapest (Icon (ICLR) 19.0x, Iqvia Holdings (IQV) 21.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Guardant Health (GH) grew revenue fastest over the trailing twelve months: Guardant Health (GH) +41.7%, Icon (ICLR) +1.8%, Iqvia Holdings (IQV) +8.8%.

Which company is more profitable?

Iqvia Holdings (IQV) has the highest net margin (Guardant Health (GH) -37.9%, Icon (ICLR) 5.4%, Iqvia Holdings (IQV) 8.1%). On return on invested capital, Iqvia Holdings (IQV) leads (Icon (ICLR) 4.7%, Iqvia Holdings (IQV) 8.2%).

Which stock has performed better?

Over the past year Guardant Health (GH) returned the most: Guardant Health (GH) +61.2%, Icon (ICLR) +19.1%, Iqvia Holdings (IQV) +18.5%. Over five years, Guardant Health (GH) compounded fastest (Guardant Health (GH) +7.9%/yr, Icon (ICLR) -7.4%/yr, Iqvia Holdings (IQV) +0.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Iqvia Holdings (IQV) has been the steadiest (Guardant Health (GH) 53.0%, Icon (ICLR) 74.9%, Iqvia Holdings (IQV) 40.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GH, ICLR and IQV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Iqvia Holdings (IQV) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.